Asset profile
BL-B01D1
Antibody–drug conjugate
Earlyevidence
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 3 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Also in development:Non-Small Cell Lung Cancer · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
119 competitors in this universe: 4 direct rivals (same mechanism and indication), 0 same-class, 115 same-indication; 82 further along in development.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| BL-B01D1: this drug | Phase 3 | Antibody–drug conjugate | EGFR + HER3 | ||
| Izalontamab Brengitecan | Phase 3 | Antibody–drug conjugate | EGFR + HER3 | ||
| SI-B001 | Phase 3 | Multispecific antibody | EGFR + HER3 | ||
| YL202 | Phase 3 | Antibody–drug conjugate | EGFR + HER3 | ||
| JS212 | Phase 2 | Antibody–drug conjugate | EGFR + HER3 | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor |
…and 104 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(47 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (18)
November 2026 (1)
Phase 3Nasopharyngeal CarcinomaActive not recruiting
Est. primary completion 2026-11 · NCT06118333 · CT.gov ↗
What to watch
December 2026 (17)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12 · NCT05470348 · CT.gov ↗
What to watch
Phase 1Locally Advanced or Metastatic Solid TumorRecruiting
Est. primary completion 2026-12 · NCT05194982 · CT.gov ↗
What to watch
Phase 1Gastrointestinal TumorRecruiting
Est. primary completion 2026-12 · NCT05262491 · CT.gov ↗
What to watch
Phase 1/2Gynecological Malignant Tumor, Solid TumorRecruiting
Est. primary completion 2026-12 · NCT05803018 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT05956587 · CT.gov ↗
What to watch
Phase 2Triple-negative Breast CancerRecruiting
Est. primary completion 2026-12 · NCT06471205 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12 · NCT06042894 · CT.gov ↗
What to watch
Phase 2Extensive-stage Small-cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT06437509 · CT.gov ↗
What to watch
Phase 2Urothelial Carcinoma, Solid TumorRecruiting
Est. primary completion 2026-12 · NCT05965856 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12 · NCT06006169 · CT.gov ↗
What to watch
Phase 2Esophageal Cancer, Gastric Cancer, Colorectal CancerRecruiting
Est. primary completion 2026-12 · NCT06008054 · CT.gov ↗
What to watch
Phase 2Cervical CancerRecruiting
Est. primary completion 2026-12 · NCT05990803 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2026-12 · NCT06405425 · CT.gov ↗
What to watch
Phase 2Urinary System Tumor, Solid TumorRecruiting
Est. primary completion 2026-12 · NCT05785039 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT05924841 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT06382129 · CT.gov ↗
What to watch
Phase 3Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT06500026 · CT.gov ↗
What to watch
2027 (12)
May 2027 (5)
Phase 2Advanced Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-05 · NCT06986785 · CT.gov ↗
What to watch
Phase 2Advanced Biliary Tract CancerRecruiting
Est. primary completion 2027-05 · NCT06978114 · CT.gov ↗
What to watch
Phase 2Cervical Cancer, Endometrial CancerRecruiting
Est. primary completion 2027-05 · NCT07054567 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05-05 · NCT06951464 · CT.gov ↗
What to watch
June 2027 (5)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06 · NCT06475300 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-06 · NCT06437522 · CT.gov ↗
What to watch
Phase 2ChordomaActive not recruiting
Est. primary completion 2027-06 · NCT06787664 · CT.gov ↗
What to watch
Phase 3Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal CancerRecruiting
Est. primary completion 2027-06 · NCT06994195 · CT.gov ↗
What to watch
Phase 3Urothelial CarcinomaRecruiting
Est. primary completion 2027-06 · NCT06857175 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-07 · NCT05880706 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-09-01 · NCT07825753 · CT.gov ↗
What to watch
2028 (7)
March 2028 (1)
Phase 2/3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-03-13 · NCT06926868 · CT.gov ↗
What to watch
December 2028 (6)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07827261 · CT.gov ↗
What to watch
Phase 2/3Castration-resistant Prostate CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07641855 · CT.gov ↗
What to watch
Phase 2/3Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-12 · NCT07554456 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12 · NCT06838273 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12 · NCT07648914 · CT.gov ↗
What to watch
Phase 3Biliary Tract CancerRecruiting
Est. primary completion 2028-12 · NCT07582315 · CT.gov ↗
What to watch
2029 (5)
January 2029 (1)
Phase 1/2Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid TumorsNot yet recruiting
Est. primary completion 2029-01-31 · NCT07307053 · CT.gov ↗
What to watch
December 2029 (4)
Phase 2/3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-12 · NCT07739199 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-12 · NCT07739186 · CT.gov ↗
What to watch
Phase 3Extensive-stage Small-cell Lung CancerRecruiting
Est. primary completion 2029-12 · NCT07502300 · CT.gov ↗
What to watch
Phase 3Triple-Negative Breast Cancer (TNBC)Recruiting
Est. primary completion 2029-12 · NCT07729956 · CT.gov ↗
What to watch
2030 (2)
2031 (1)
December 2031 (1)
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-12-30 · NCT07680790 · CT.gov ↗
What to watch
2032 (1)
December 2032 (1)
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-12 · NCT07642024 · CT.gov ↗
What to watch
2033 (1)
December 2033 (1)
Phase 3Nasopharyngeal Carcinoma (NPC)Not yet recruiting
Est. primary completion 2033-12 · NCT07783321 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.